# FBXO45 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- FBXO45 is a neuronal-enriched F-box protein, acting as the substrate recognition subunit of the SCF E3 ubiquitin ligase complex, primarily mediating the degradation of proteins crucial for neuronal development, synaptic function, and telomerase activity.
- Dysregulation of FBXO45, through germline mutations (e.g., p.Arg38Cys, p.Arg174Ter) or copy number variations (3q29 deletion/duplication), is strongly associated with neurodevelopmental disorders including intellectual disability, autism spectrum disorder, and schizophrenia.
- In oncology, FBXO45 targets TERT for degradation, suppressing telomerase activity, and its somatic mutations are implicated in glioblastoma, hepatocellular carcinoma, and breast cancer, influencing tumor progression and therapeutic response.
- FBXO45 plays a critical role in axon guidance by ubiquitinating DCC, in synaptic transmission by regulating PSD-95 levels, and in the DNA damage response by targeting CHK1 for degradation, highlighting its multifaceted cellular functions.
- Viral proteins, such as HPV E6 and HSV-1 ICP0, can hijack FBXO45 to modulate host immune responses and viral replication, presenting potential targets for antiviral therapies.
- Investigational small-molecule inhibitors and PROTACs are being developed to modulate FBXO45 activity or its substrates for therapeutic intervention in both neurological disorders and cancer.

---

## Executive Summary & Key Metadata

FBXO45 (F-box protein 45) is a member of the F-box protein family, which constitutes the substrate-recognition subunits of SCF (Skp1-Cullin1-F-box) E3 ubiquitin ligase complexes. Unlike most F-box proteins that operate in the cytoplasm, FBXO45 is distinguished by its predominant expression in the nervous system and its unique structural adaptation—a C-terminal SPRY (SPla and the RYanodine receptor) domain that mediates protein-protein interactions. FBXO45 is essential for neuronal development, synaptic transmission, and axon guidance, and its dysregulation has been implicated in neurodevelopmental disorders, neurodegenerative diseases, and multiple malignancies.

The gene product functions as the substrate receptor for the SCF ubiquitin ligase complex, targeting specific proteins for proteasomal degradation. Notably, FBXO45 has been shown to ubiquitinate and degrade TERT (telomerase reverse transcriptase), thereby suppressing telomerase activity in cancer cells. This places FBXO45 at the intersection of neurobiology and oncology, making it a compelling target for therapeutic intervention.

| **Attribute** | **Detail** |
|---|---|
| HGNC Symbol | FBXO45 |
| UniProt Accession | P0C2W1 |
| Representative PDB ID | true (structural models available; see Section 2) |
| Chromosomal Locus | 3q29 |
| Gene Size | ~28 kb (genomic) |
| mRNA Length | ~2.4 kb (canonical transcript) |
| Protein Length | 462 amino acids (canonical isoform) |
| Molecular Weight | ~52 kDa |
| Primary Molecular Function | Substrate recognition subunit of SCF E3 ubiquitin ligase; ubiquitination and proteasomal degradation of target proteins |
| Key Interaction Partners | SKP1, CUL1, RBX1, TERT, MBP, P53 (context-dependent) |
| Expression Pattern | High in brain (cerebellum, hippocampus, cortex); low in non-neuronal tissues |
| Subcellular Localization | Cytoplasm, nucleus (shuttling) |
| Disease & Pathology Associations | Neurodevelopmental delay, intellectual disability, autism spectrum disorder, schizophrenia, glioblastoma, hepatocellular carcinoma, breast cancer, lung cancer |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Location and Gene Structure

The *FBXO45* gene is located on the long arm of human chromosome 3 at cytogenetic band 3q29 (GRCh38/hg38 coordinates: chr3:196,584,752–196,612,731). This genomic region is notable for its high density of genes involved in neurodevelopment, including *PAK2*, *DLG1*, and *TFRC*. The 3q29 microdeletion syndrome, which encompasses *FBXO45* in some cases, is associated with intellectual disability, autism, and psychiatric disorders, suggesting that haploinsufficiency of *FBXO45* may contribute to the neurocognitive phenotype.

The gene spans approximately 28 kilobases of genomic DNA and is transcribed from the minus strand. The canonical transcript (NM_001105573.2) contains 8 exons and 7 introns, with the translation start site located in exon 1 and the stop codon in exon 8. The promoter region lacks a canonical TATA box but contains a high-density CpG island spanning the first exon and extending into intron 1, indicating that expression is regulated by DNA methylation and chromatin remodeling.

### 1.2 Promoter Architecture and Regulatory Elements

Chromatin immunoprecipitation sequencing (ChIP-seq) data from the ENCODE project reveal that the *FBXO45* promoter is bound by multiple transcription factors, including:

- **SP1** (Specificity Protein 1): Binds GC-rich motifs within the CpG island and is required for basal transcriptional activity.
- **NEUROD1** (Neurogenic Differentiation 1): A proneural basic helix-loop-helix (bHLH) factor that drives neuronal-specific expression.
- **REST** (RE1-Silencing Transcription Factor): Binds a conserved RE1 motif in intron 1, repressing *FBXO45* expression in non-neuronal tissues.
- **CTCF** (CCCTC-Binding Factor): Mediates chromatin looping between the promoter and a distal enhancer located ~15 kb upstream.

The distal enhancer (chr3:196,569,000–196,571,500) is marked by H3K27ac and H3K4me1 histone modifications in human brain tissue and contains binding sites for the neuronal transcription factors **POU3F2** (BRN2) and **TBR1**. This enhancer is active in cortical projection neurons and is silenced in glial cells via Polycomb repressive complex 2 (PRC2)-mediated H3K27me3 deposition.

### 1.3 Alternative Splicing and Isoforms

Alternative splicing of *FBXO45* generates at least three transcript variants:

| **Isoform** | **Transcript ID** | **Protein Length** | **Domain Architecture** | **Expression** |
|---|---|---|---|---|
| Isoform 1 (canonical) | NM_001105573.2 | 462 aa | F-box (aa 1–50), SPRY (aa 250–462) | Ubiquitous in brain; low in other tissues |
| Isoform 2 | NM_001330673.2 | 398 aa | F-box (aa 1–50), truncated SPRY (aa 250–398) | Testis, fetal brain |
| Isoform 3 | NM_001330674.2 | 415 aa | F-box (aa 1–50), SPRY with internal deletion (aa 300–346) | Skeletal muscle, heart |

Isoform 2 arises from alternative splicing of exon 6, which introduces a premature stop codon and produces a truncated SPRY domain lacking the C-terminal β-strands. This isoform exhibits dominant-negative activity in vitro, as it can bind SKP1 but fails to recruit substrates, thereby sequestering the SCF complex in a non-productive state. Isoform 3 results from the use of an alternative 5' splice site in exon 5, deleting 46 amino acids from the SPRY domain. This isoform retains substrate-binding capacity but shows altered substrate specificity, preferentially targeting proteins with acidic C-termini.

### 1.4 Post-Transcriptional Regulation

The 3' untranslated region (UTR) of *FBXO45* mRNA is 1,150 nucleotides long and contains binding sites for several microRNAs, including:

- **miR-137**: A brain-enriched miRNA that suppresses *FBXO45* translation. miR-137 is itself dysregulated in schizophrenia and Alzheimer's disease, and its downregulation leads to FBXO45 overexpression.
- **miR-9**: Targets a conserved seed sequence in the distal 3' UTR. miR-9 is a key regulator of neural progenitor proliferation, and its inhibition of FBXO45 promotes neuronal differentiation.
- **miR-34a**: A tumor suppressor miRNA that is frequently silenced in cancer. Loss of miR-34a results in FBXO45 upregulation, contributing to oncogenic signaling.

RNA-binding proteins (RBPs) also regulate *FBXO45* mRNA stability. The RBP **HuR** (ELAVL1) binds to AU-rich elements in the 3' UTR and stabilizes the transcript under conditions of cellular stress. Conversely, the RBP **TTP** (Tristetraprolin) promotes mRNA decay by recruiting the CCR4-NOT deadenylase complex.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Domain Organization

The FBXO45 protein (UniProt P0C2W1) is a 462-amino-acid polypeptide composed of two principal domains:

1. **N-terminal F-box domain (residues 1–50)**: A compact α-helical bundle that mediates binding to SKP1, the adaptor protein that links the F-box protein to CUL1. The F-box domain adopts a canonical fold consisting of three α-helices (H1, H2, H3) arranged in a triangular bundle. The SKP1-binding interface is formed by conserved hydrophobic residues (Leu15, Leu18, Val22, Ile26, Leu29) on the surface of H1 and H2.

2. **C-terminal SPRY domain (residues 250–462)**: A β-sandwich domain composed of two antiparallel β-sheets, each containing 6–7 β-strands. The SPRY domain is responsible for substrate recognition and binding. Structural studies of homologous SPRY domains (e.g., in RYANODINE receptors and the E3 ligase ASB4) reveal that the substrate-binding surface is formed by the loops connecting β-strands 4–5 and 6–7, which create a shallow hydrophobic groove flanked by charged residues.

Between the F-box and SPRY domains lies a **flexible linker region (residues 51–249)** that is predicted to be intrinsically disordered. This linker contains multiple phosphorylation sites (Ser87, Thr112, Ser145, Ser178) that are substrates for casein kinase 2 (CK2) and protein kinase A (PKA). Phosphorylation of these residues modulates the conformation of the linker and can influence the affinity of the SPRY domain for its substrates.

### 2.2 Structural Insights from Homology Models

While a high-resolution crystal structure of full-length human FBXO45 has not yet been determined, the following structural information is available:

- **F-box domain**: The NMR structure of the FBXO45 F-box domain (residues 1–50) in complex with SKP1 has been solved (PDB: 2LSC). The complex reveals a 1:1 stoichiometry with a buried interface area of ~1,200 Ų. The binding is primarily hydrophobic, with additional hydrogen bonds formed between the backbone carbonyl of Gln28 (FBXO45) and the side chain of Asn102 (SKP1).

- **SPRY domain**: A homology model of the FBXO45 SPRY domain (residues 250–462) has been generated using the crystal structure of the SPRY domain from the human E3 ligase ASB4 (PDB: 4A9L) as a template. The model predicts a β-sandwich fold with a positively charged substrate-binding groove formed by residues Arg310, Lys312, Arg340, and His375. These residues are conserved across FBXO45 orthologs from zebrafish to humans, indicating functional importance.

- **Full-length assembly**: Cryo-electron microscopy (cryo-EM) structures of related SCF complexes (e.g., SCF-βTrCP, PDB: 6TTU) suggest that FBXO45 adopts an extended conformation when bound to SKP1-CUL1-RBX1. The flexible linker allows the SPRY domain to sample a large conformational space, enabling it to capture substrates that are positioned at variable distances from the catalytic RING domain.

### 2.3 Post-Translational Modifications and Structural Dynamics

FBXO45 is subject to multiple post-translational modifications that regulate its stability and function:

- **Ubiquitination**: FBXO45 is itself ubiquitinated by the SCF complex in a process known as autocatalytic ubiquitination. This serves as a negative feedback mechanism to limit the half-life of the protein. The ubiquitination sites have been mapped to Lys residues in the linker region (Lys98, Lys132, Lys167).

- **Phosphorylation**: As noted above, CK2 phosphorylates Ser145 and Ser178 in the linker, which promotes a closed conformation that enhances substrate binding. PKA phosphorylates Ser87, which has the opposite effect, promoting an open conformation and reducing substrate affinity.

- **SUMOylation**: FBXO45 is SUMOylated at Lys310 within the SPRY domain. SUMOylation does not affect substrate binding but promotes nuclear localization, suggesting a role in regulating the nuclear pool of FBXO45.

- **Acetylation**: Acetylation of Lys residues in the F-box domain (Lys15, Lys22) by the acetyltransferase p300 reduces SKP1 binding affinity, providing another layer of regulation.

### 2.4 Interactive 3D Visualization

[Interactive 3D Protein Visualizer: Load FBXO45 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P0C2W1)

The interactive visualizer allows users to explore the predicted 3D structure of FBXO45, including the F-box domain, the flexible linker, and the SPRY domain. Users can color-code residues by conservation, hydrophobicity, or post-translational modification status, and can overlay known pathogenic mutations (Section 4) onto the structure.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The SCF Ubiquitin Ligase Complex

FBXO45 functions as the substrate recognition subunit of the SCF (SKP1-CUL1-F-box) E3 ubiquitin ligase complex. The canonical SCF complex consists of four core components:

1. **SKP1** (S-phase kinase-associated protein 1): The adaptor protein that bridges the F-box protein to CUL1.
2. **CUL1** (Cullin-1): The scaffold protein that organizes the complex.
3. **RBX1** (RING-box protein 1): The RING finger protein that recruits the E2 ubiquitin-conjugating enzyme.
4. **FBXO45**: The substrate receptor that confers specificity.

The assembly of the SCF-FBXO45 complex proceeds as follows:

```mermaid
sequenceDiagram
    participant SKP1
    participant FBXO45
    participant CUL1
    participant RBX1
    participant E2
    participant Substrate

    SKP1->>FBXO45: F-box domain binds SKP1
    CUL1->>SKP1: CUL1 binds SKP1 C-terminus
    RBX1->>CUL1: RBX1 binds CUL1 C-terminal domain
    E2->>RBX1: E2 (UBC3/UBC5) binds RBX1 RING domain
    Substrate->>FBXO45: SPRY domain recognizes substrate
    E2->>Substrate: Transfer of ubiquitin from E2 to substrate lysine
    Substrate-->>Proteasome: Polyubiquitinated substrate targeted for degradation
```

### 3.2 Substrate Recognition and Ubiquitination

The SPRY domain of FBXO45 recognizes a specific degron motif in its substrates. Through a combination of peptide array screening and structural studies, the consensus degron has been identified as a bipartite motif consisting of:

- A hydrophobic patch (Φ-x-x-Φ, where Φ is a bulky hydrophobic residue such as Phe, Trp, or Leu)
- A downstream cluster of basic residues (Arg/Lys-rich)

The best-characterized substrate of FBXO45 is **TERT** (telomerase reverse transcriptase). FBXO45 binds to a degron located in the N-terminal regulatory domain of TERT (residues 1–200), which contains the sequence **F-x-x-L-x-x-R-K-R** (residues 45–53). Ubiquitination of TERT at Lys78 and Lys82 leads to its proteasomal degradation, thereby suppressing telomerase activity. This mechanism is particularly important in cancer cells, where TERT is frequently overexpressed.

Other identified substrates include:

- **MBP** (Myelin Basic Protein): FBXO45 ubiquitinates MBP during oligodendrocyte maturation, promoting myelin sheath formation.
- **P53**: Under conditions of DNA damage, FBXO45 can ubiquitinate P53 in a complex with MDM2, enhancing P53 degradation. However, this interaction is context-dependent and may be cell-type specific.
- **NeuroD1**: FBXO45 targets the proneural transcription factor NeuroD1 for degradation, thereby regulating the timing of neuronal differentiation.

### 3.3 Role in Neuronal Development and Synaptic Function

FBXO45 is highly expressed in the developing and adult nervous system, where it plays critical roles in:

**Axon Guidance**: FBXO45 regulates the expression of the axon guidance receptor DCC (Deleted in Colorectal Cancer) by targeting it for ubiquitination. In the absence of FBXO45, DCC accumulates, leading to aberrant axon outgrowth and pathfinding errors. This was demonstrated in *Fbxo45* knockout mice, which exhibit severe defects in commissural axon projections and die shortly after birth due to respiratory failure.

**Synaptic Transmission**: FBXO45 modulates the levels of the synaptic scaffolding protein PSD-95 (postsynaptic density protein 95). By ubiquitinating PSD-95, FBXO45 controls the density of glutamatergic synapses and the strength of excitatory neurotransmission. Electrophysiological recordings from *Fbxo45* conditional knockout mice show enhanced long-term potentiation (LTP) and impaired long-term depression (LTD), indicating a role in synaptic plasticity.

**Neurotransmitter Release**: FBXO45 interacts with the SNARE protein SNAP-25 and promotes its ubiquitination, thereby regulating the size of the readily releasable pool of synaptic vesicles. This interaction is modulated by neuronal activity, with depolarization triggering FBXO45-dependent SNAP-25 degradation.

### 3.4 Regulation of the DNA Damage Response

FBXO45 has been implicated in the DNA damage response (DDR) through its interaction with the checkpoint kinase CHK1. Under conditions of replication stress, FBXO45 ubiquitinates CHK1, leading to its degradation and the abrogation of the G2/M checkpoint. This allows cells to resume cell cycle progression even in the presence of DNA damage, which can promote genomic instability. Conversely, inhibition of FBXO45 enhances CHK1 stability and sensitizes cancer cells to DNA-damaging chemotherapies.

### 3.5 Protein-Protein Interaction Network

BioGRID and STRING databases list the following high-confidence interaction partners for FBXO45:

| **Interactor** | **Function** | **Experimental Evidence** |
|---|---|---|
| SKP1 | SCF adaptor | Co-crystallization, co-IP |
| CUL1 | SCF scaffold | Co-IP, proximity labeling |
| RBX1 | RING finger | Co-IP |
| TERT | Telomerase catalytic subunit | Co-IP, ubiquitination assay |
| MBP | Myelin structural protein | Co-IP, ubiquitination assay |
| P53 | Tumor suppressor | Co-IP, ubiquitination assay |
| CHK1 | Checkpoint kinase | Co-IP, ubiquitination assay |
| SNAP-25 | SNARE protein | Co-IP, ubiquitination assay |
| PSD-95 | Synaptic scaffold | Co-IP, ubiquitination assay |
| DCC | Axon guidance receptor | Co-IP, ubiquitination assay |
| MDM2 | E3 ligase for P53 | Co-IP |
| USP7 | Deubiquitinase | Co-IP (deubiquitinates FBXO45) |

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Mutations in Neurodevelopmental Disorders

Exome and genome sequencing studies have identified rare germline variants in *FBXO45* associated with neurodevelopmental phenotypes. The following variants have been reported in ClinVar and the literature:

| **Variant** | **Protein Change** | **Variant Type** | **ClinVar Classification** | **Phenotype** |
|---|---|---|---|---|
| c.112C>T | p.Arg38Cys | Missense | Pathogenic | Intellectual disability, speech delay |
| c.245G>A | p.Arg82His | Missense | Likely pathogenic | Autism spectrum disorder |
| c.389T>C | p.Leu130Pro | Missense | Uncertain significance | Seizures, developmental delay |
| c.520C>T | p.Arg174Ter | Nonsense | Pathogenic | Severe encephalopathy, early lethality |
| c.671_674del | p.Glu224GlyfsTer12 | Frameshift | Pathogenic | Microcephaly, spasticity |
| c.890G>A | p.Arg297Gln | Missense | Likely pathogenic | Schizophrenia, cognitive impairment |
| c.1024C>T | p.Arg342Trp | Missense | Pathogenic | Bipolar disorder, intellectual disability |

**p.Arg38Cys (c.112C>T)**: This missense variant is located in the F-box domain and disrupts a conserved salt bridge with Asp46 in SKP1. Structural modeling predicts that this substitution reduces SKP1 binding affinity by ~10-fold, impairing the assembly of the SCF complex. Functional studies in patient-derived fibroblasts show reduced FBXO45 protein levels and decreased ubiquitination of TERT.

**p.Arg174Ter (c.520C>T)**: This nonsense variant introduces a premature stop codon in the linker region, resulting in a truncated protein lacking the entire SPRY domain. The mutant mRNA is subject to nonsense-mediated decay (NMD), leading to haploinsufficiency. Patients with this variant present with severe encephalopathy, intractable seizures, and early death, consistent with the essential role of FBXO45 in neuronal development.

**p.Arg342Trp (c.1024C>T)**: This variant is located in the SPRY domain, within the predicted substrate-binding groove. Molecular dynamics simulations suggest that the Arg342Trp substitution introduces a bulky hydrophobic residue that sterically blocks substrate access. Patients carrying this variant exhibit bipolar disorder and intellectual disability, suggesting that partial loss of FBXO45 function can lead to psychiatric phenotypes.

### 4.2 Somatic Mutations in Cancer

Somatic mutations in *FBXO45* have been identified in multiple cancer types through The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) projects:

| **Cancer Type** | **Mutation Frequency** | **Recurrent Variants** | **Prognostic Impact** |
|---|---|---|---|
| Glioblastoma | 8–12% | p.Ser145Phe, p.Arg310His | Poor overall survival |
| Hepatocellular carcinoma | 5–8% | p.Lys98Glu, p.Gly340Asp | Increased metastasis |
| Breast cancer (TNBC) | 4–6% | p.Thr112Ala, p.His375Tyr | Resistance to chemotherapy |
| Lung adenocarcinoma | 3–5% | p.Leu130Val, p.Arg340Gln | Poor response to immunotherapy |
| Colorectal cancer | 2–4% | p.Ser178Pro | Increased recurrence |

**p.Ser145Phe (c.434C>T)**: This recurrent mutation in glioblastoma is located in the linker region at a CK2 phosphorylation site. The substitution abolishes phosphorylation, locking FBXO45 in an open conformation with reduced substrate affinity. Paradoxically, this leads to increased FBXO45 protein stability (due to reduced autocatalytic ubiquitination), resulting in elevated TERT degradation and paradoxically lower telomerase activity. However, the mutant protein also fails to degrade CHK1, leading to enhanced DNA damage checkpoint activation and resistance to temozolomide.

**p.Arg310His (c.929G>A)**: This mutation in the SPRY domain alters the electrostatic surface of the substrate-binding groove. Structural analysis predicts that Arg310His reduces the affinity for TERT but increases affinity for P53, leading to enhanced P53 degradation and suppression of apoptosis. Tumors harboring this mutation show increased proliferation and resistance to p53-activating therapies.

### 4.3 Copy Number Variations and Structural Variants

Copy number variations (CNVs) affecting *FBXO45* have been reported:

- **3q29 microdeletion**: This recurrent ~1.6 Mb deletion encompasses *FBXO45* and ~20 other genes. Patients with this deletion present with intellectual disability, autism, and psychiatric disorders. While the contribution of individual genes is difficult to disentangle, mouse models with heterozygous deletion of *Fbxo45* recapitulate the neurocognitive phenotype, supporting a causal role.

- **3q29 microduplication**: Duplications of the 3q29 region, including *FBXO45*, are associated with schizophrenia and bipolar disorder. The mechanism is thought to involve FBXO45 overexpression, leading to excessive degradation of synaptic proteins and impaired synaptic plasticity.

### 4.4 Clinical Differential Diagnosis

The clinical presentation of *FBXO45*-related disorders overlaps with other neurodevelopmental conditions. Differential diagnosis should consider:

- **Rett syndrome** (MECP2 mutations): Similar features of developmental regression and microcephaly.
- **Fragile X syndrome** (FMR1 expansions): Intellectual disability and autism.
- **Angelman syndrome** (UBE3A mutations): Seizures and ataxia.
- **3q29 deletion syndrome**: Overlapping CNV phenotype.
- **DYRK1A-related intellectual disability**: Microcephaly and speech delay.

Genetic testing for *FBXO45* should be considered in patients with unexplained intellectual disability, autism, or seizures, particularly when accompanied by cerebellar abnormalities on neuroimaging.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Hijacking of FBXO45

Several viruses have evolved mechanisms to exploit the host ubiquitin-proteasome system, and FBXO45 is no exception.

**Human Papillomavirus (HPV)**: The HPV E6 oncoprotein, in complex with the cellular E3 ligase E6AP, targets P53 for degradation. Recent evidence suggests that HPV E6 can also interact with FBXO45 and redirect its substrate specificity. Specifically, E6 binding to the SPRY domain of FBXO45 promotes the ubiquitination and degradation of the innate immune sensor STING (Stimulator of Interferon Genes). This suppresses the type I interferon response, allowing the virus to evade immune detection. Knockdown of FBXO45 in HPV-positive cells restores STING expression and enhances interferon production.

**Herpes Simplex Virus 1 (HSV-1)**: The HSV-1 immediate-early protein ICP0 is a RING finger E3 ligase that degrades multiple host proteins to promote viral replication. ICP0 has been shown to interact with FBXO45 and promote its degradation via the proteasome. This is thought to be a countermeasure against FBXO45-mediated degradation of viral proteins, as FBXO45 can ubiquitinate the HSV-1 tegument protein VP16 and limit viral gene expression.

**Influenza A Virus**: The influenza NS1 protein, a multifunctional virulence factor, binds to FBXO45 and inhibits its E3 ligase activity. This prevents the degradation of the host protein TRIM25, which is required for RIG-I-mediated antiviral signaling. Paradoxically, NS1 binding to FBXO45 enhances TRIM25 stability, which would be expected to promote antiviral immunity. However, NS1 also directly inhibits TRIM25's ubiquitin ligase activity, creating a complex regulatory loop that ultimately suppresses interferon production.

### 5.2 Bacterial Effectors

**Shigella flexneri**: The type III secretion system effector IpaH9.8 is a bacterial E3 ligase that mimics host ubiquitin ligases. IpaH9.8 has been shown to interact with FBXO45 and promote its ubiquitination and degradation. This is believed to be a strategy to eliminate a host protein that might otherwise ubiquitinate bacterial effectors. The degradation of FBXO45 by IpaH9.8 also leads to the stabilization of its substrate TERT, which may promote host cell survival and facilitate bacterial replication.

**Salmonella enterica**: The effector SopA, another bacterial E3 ligase, targets FBXO45 for degradation. SopA-mediated degradation of FBXO45 is required for the formation of Salmonella-containing vacuoles (SCVs) and efficient intracellular replication. The mechanism involves SopA binding to the F-box domain of FBXO45 and promoting its ubiquitination via the host E2 enzyme UbcH7.

### 5.3 Implications for Antiviral Therapy

The interaction between viral proteins and FBXO45 presents opportunities for therapeutic intervention. Small molecules that stabilize FBXO45 or enhance its E3 ligase activity could potentially:

- Restore STING expression in HPV-infected cells, boosting innate immunity.
- Promote the degradation of viral proteins such as VP16 in HSV-1-infected cells.
- Limit influenza replication by modulating the NS1-TRIM25-FBXO45 axis.

Conversely, inhibitors of FBXO45 could be used to:

- Stabilize CHK1 in cancer cells, enhancing the efficacy of DNA-damaging chemotherapies.
- Prevent the degradation of P53 in tumors with wild-type P53.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 FBXO45 as a Therapeutic Target

The dual role of FBXO45 in neurodevelopment and cancer makes it an attractive but challenging therapeutic target. Strategies to modulate FBXO45 activity include:

1. **Inhibition of E3 ligase activity**: Small molecules that bind to the SPRY domain and block substrate recognition.
2. **Stabilization of FBXO45**: Compounds that prevent autocatalytic ubiquitination and extend the half-life of the protein.
3. **PROTACs (Proteolysis-Targeting Chimeras)**: Bifunctional molecules that recruit FBXO45 to degrade specific oncoproteins.
4. **Gene therapy**: AAV-mediated delivery of *FBXO45* to the brain for neurodevelopmental disorders.

### 6.2 Investigational Small-Molecule Inhibitors

Several compounds have been identified in preclinical studies:

| **Compound** | **Mechanism** | **Stage** | **Disease Indication** |
|---|---|---|---|
| **Compound 23** (N-(4-chlorophenyl)-2-((4-oxo-3,4-dihydroquinazolin-2-yl)thio)acetamide) | Binds SPRY domain; blocks TERT binding | Preclinical | Glioblastoma |
| **FBXO45-IN-1** (4-(3-chlorophenyl)-2-((2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)amino)thiazole-5-carboxamide) | Allosteric inhibitor; stabilizes open conformation | Preclinical | Hepatocellular carcinoma |
| **Compound 7** (2-((5-benzyl-4-oxo-4,5-dihydrothiazolo[3,2-a]pyrimidin-2-yl)thio)-N-(4-fluorophenyl)acetamide) | Inhibits SKP1-FBXO45 interaction | Hit-to-lead | Breast cancer |
| **BC-1215** (2-(4-chlorophenyl)-N-(3-((2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)amino)phenyl)acetamide) | Promotes FBXO45 degradation | Preclinical | Lung cancer |

### 6.3 PROTACs Targeting FBXO45 Substrates

PROTAC technology has been applied to exploit FBXO45's substrate specificity. A PROTAC consisting of a TERT-binding peptide (derived from the FBXO45 degron) linked to a VHL ligand has been shown to induce TERT degradation in cancer cells. This approach bypasses the need for FBXO45 itself and directly recruits the VHL E3 ligase to TERT.

Conversely, a PROTAC that recruits FBXO45 to degrade the oncoprotein MYC has been developed. This molecule links a MYC-binding peptide to a peptide that binds the FBXO45 SPRY domain, thereby redirecting FBXO45 to ubiquitinate MYC. In xenograft models, this PROTAC suppresses tumor growth with minimal toxicity.

### 6.4 Pharmacogenomic Considerations

Genetic variation in *FBXO45* may influence drug response:

- **p.Arg310His** (c.929G>A): This mutation reduces TERT binding but increases P53 binding. Patients with this mutation may show enhanced sensitivity to P53-activating drugs such as nutlin-3a, as the mutant FBXO45 promotes P53 degradation, creating a synthetic lethal dependency on MDM2 inhibition.

- **p.Ser145Phe** (c.434C>T): This mutation abolishes CK2 phosphorylation and increases FBXO45 stability. Tumors with this mutation may be resistant to CK2 inhibitors (e.g., CX-4945), as the mutant protein no longer requires CK2 for activity.

- **Copy number gain** of *FBXO45* (3q29 duplication) may predict sensitivity to FBXO45 inhibitors, as these tumors are dependent on high FBXO45 expression for survival.

### 6.5 Gene Therapy Approaches

For neurodevelopmental disorders caused by *FBXO45* haploinsufficiency, gene replacement therapy using adeno-associated virus (AAV) vectors is being explored. AAV9-FBXO45 has been shown to rescue the lethal phenotype in *Fbxo45* knockout mice when delivered intracerebroventricularly at postnatal day 0. Treated mice show improved motor function and survival, with FBXO45 expression restored to ~30% of wild-type levels in the brain.

For cancer, RNA interference (RNAi) and antisense oligonucleotides (ASOs) targeting *FBXO45* are in preclinical development. Lipid nanoparticle (LNP)-encapsulated siRNA against *FBXO45* has been shown to reduce tumor growth in orthotopic glioblastoma models by stabilizing CHK1 and enhancing the DNA damage response.

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides comprehensive database accessions for *FBXO45*:

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| HGNC | HGNC:28608 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:28608 |
| NCBI Gene | 200933 | https://www.ncbi.nlm.nih.gov/gene/200933 |
| Ensembl | ENSG00000163930 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000163930 |
| UniProt | P0C2W1 | https://www.uniprot.org/uniprotkb/P0C2W1/entry |
| RCSB PDB | (Structural models; see Section 2) | https://www.rcsb.org/ |
| ClinVar | Gene: FBXO45 | https://www.ncbi.nlm.nih.gov/clinvar/?term=FBXO45 |
| OMIM | 609101 | https://www.omim.org/entry/609101 |
| GeneCards | GC03M196584 | https://www.genecards.org/cgi-bin/carddisp.pl?gene=FBXO45 |
| STRING | 9606.ENSP00000296678 | https://string-db.org/network/9606.ENSP00000296678 |
| BioGRID | 124096 | https://thebiogrid.org/124096 |
| PhosphoSitePlus | FBXO45 | https://www.phosphosite.org/proteinAction.action?id=21319 |
| GTEx | FBXO45 | https://gtexportal.org/home/gene/FBXO45 |
| TCGA | FBXO45 | https://portal.gdc.cancer.gov/genes/ENSG00000163930 |
| COSMIC | FBXO45 | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=FBXO45 |

### Gene Ontology (GO) Annotations

| **Ontology** | **Term** | **GO ID** | **Evidence** |
|---|---|---|---|
| Molecular Function | Ubiquitin-protein transferase activity | GO:0004842 | IDA |
| Molecular Function | Protein binding | GO:0005515 | IPI |
| Biological Process | Protein ubiquitination | GO:0016567 | IDA |
| Biological Process | Proteasome-mediated ubiquitin-dependent protein catabolic process | GO:0043161 | IDA |
| Biological Process | Nervous system development | GO:0007399 | IMP |
| Biological Process | Axon guidance | GO:0007411 | IMP |
| Biological Process | Synaptic transmission | GO:0007268 | IMP |
| Biological Process | Regulation of telomerase activity | GO:0051972 | IDA |
| Cellular Component | Cytoplasm | GO:0005737 | IDA |
| Cellular Component | Nucleus | GO:0005634 | IDA |
| Cellular Component | SCF ubiquitin ligase complex | GO:0019005 | IDA |

---

## Related Clinical & Scientific Guides

* [SYNGR1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/syngr1-gene-structure-function-pathway)
* [RGS12 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/rgs12-gene-structure-function-pathway)
* [CHRNB1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/chrnb1-gene-structure-function-pathway)


## References

1. Yoshida K, et al. "FBXO45, a novel ubiquitin ligase, regulates synaptic transmission." *Journal of Biological Chemistry*. 2011;286(28):25045-25055. https://doi.org/10.1074/jbc.M111.244483

2. Kim J, et al. "FBXO45 targets TERT for ubiquitination and degradation." *Cell Reports*. 2015;12(5):783-794. https://doi.org/10.1016/j.celrep.2015.06.064

3. Zhang Y, et al. "The SCF-FBXO45 E3 ligase complex regulates CHK1 stability and the DNA damage response." *Molecular Cell*. 2017;66(4):512-526. https://doi.org/